Rifampicin Mono-Resistant Tuberculosis—A Review of an Uncommon But Growing Challenge for Global Tuberculosis Control

Author:

Malenfant Jason H1ORCID,Brewer Timothy F23

Affiliation:

1. Public Health & Preventive Medicine Program, UCLA David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA

2. Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, USA

3. Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California, USA

Abstract

Abstract Tuberculosis (TB) remains the leading cause of death by an infectious pathogen worldwide, and drug-resistant TB is a critical and rising obstacle to global control efforts. Most scientific studies and global TB efforts have focused on multidrug-resistant TB (MDR-TB), meaning isolates resistant to both isoniazid (INH) and rifampicin (RIF). Newer diagnostic tests are resulting in an increasing awareness of RIF-resistant TB in addition to MDR disease. To date, RIF resistance has been assumed to be synonymous with MDR-TB, but this approach may expose TB patients with RIF mono-resistance disease to unnecessarily long and toxic treatment regimens. We review what is currently known about RIF mono-resistant TB, its history and epidemiology, mechanisms of RIF resistance, available diagnostic techniques, treatment outcomes reported globally, and future directions for combatting this disease.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Reference79 articles.

1. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries;Espinal;JAMA,2000

2. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000;Santha;Int J Tuberc Lung Dis,2002

3. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru;Suárez;Lancet,2002

4. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru;Kawai;Am J Trop Med Hyg,2006

Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3